Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
GO-A-HAM:
Gemtuzumab Ozogamicin 3g/m² day 1 Cytarabine 3g/m² bid days 1-3 Mitoxantrone 12mg/m² days 2,3
All-trans Retinoic acid 45mg/m² days 4-6 and 15 mg/m² days 7-28